| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Increase of regulatory T cells in the peripheral blood of cancer patients.
|
Clin Cancer Res
|
2003
|
3.44
|
|
2
|
Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes.
|
Biochem Biophys Res Commun
|
2004
|
3.21
|
|
3
|
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
|
Blood
|
2013
|
2.34
|
|
4
|
Remission of recalcitrant dermatomyositis treated with ruxolitinib.
|
N Engl J Med
|
2014
|
2.07
|
|
5
|
The effect of zoledronic acid on the function and differentiation of myeloid cells.
|
Haematologica
|
2006
|
1.66
|
|
6
|
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats.
|
Blood
|
2011
|
1.63
|
|
7
|
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression.
|
J Immunol
|
2010
|
1.52
|
|
8
|
Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy.
|
Diabetes
|
2011
|
1.52
|
|
9
|
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
|
Blood
|
2013
|
1.42
|
|
10
|
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease.
|
Clin Immunol
|
2004
|
1.26
|
|
11
|
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation.
|
Proc Natl Acad Sci U S A
|
2005
|
1.23
|
|
12
|
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.
|
Biochem Biophys Res Commun
|
2007
|
1.16
|
|
13
|
Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice.
|
J Hepatol
|
2005
|
1.07
|
|
14
|
The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism.
|
Circ Res
|
2010
|
1.04
|
|
15
|
Endothelial progenitor cells: a source for therapeutic vasculogenesis?
|
J Cell Mol Med
|
2004
|
0.97
|
|
16
|
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.
|
Exp Hematol
|
2005
|
0.97
|
|
17
|
Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism.
|
Circ Res
|
2009
|
0.95
|
|
18
|
Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
|
Immunol Cell Biol
|
2011
|
0.94
|
|
19
|
The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
|
J Immunol
|
2009
|
0.93
|
|
20
|
CD34+/CD133- circulating endothelial precursor cells (CEP): characterization, senescence and in vivo application.
|
Exp Gerontol
|
2006
|
0.92
|
|
21
|
Hearing assessment in dental practitioners and other academic professionals from an urban setting.
|
Head Face Med
|
2014
|
0.89
|
|
22
|
High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer.
|
Hum Pathol
|
2011
|
0.88
|
|
23
|
Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
|
PLoS One
|
2012
|
0.87
|
|
24
|
State dependent posterior hippocampal volume increases in patients with major depressive disorder.
|
J Affect Disord
|
2011
|
0.87
|
|
25
|
Role of forkhead box protein 3 expression in invasive breast cancer.
|
J Clin Oncol
|
2007
|
0.87
|
|
26
|
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.
|
Int J Cancer
|
2009
|
0.86
|
|
27
|
Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure.
|
J Thorac Cardiovasc Surg
|
2006
|
0.85
|
|
28
|
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
|
Haematologica
|
2010
|
0.85
|
|
29
|
Releasing the brake: targeting Cbl-b to enhance lymphocyte effector functions.
|
Clin Dev Immunol
|
2012
|
0.84
|
|
30
|
High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.
|
Gynecol Oncol
|
2010
|
0.83
|
|
31
|
The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
|
Biol Blood Marrow Transplant
|
2009
|
0.82
|
|
32
|
DyeCycle Violet used for side population detection is a substrate of P-glycoprotein.
|
Cytometry A
|
2012
|
0.82
|
|
33
|
Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells.
|
Clin Breast Cancer
|
2013
|
0.80
|
|
34
|
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.
|
Wien Klin Wochenschr
|
2008
|
0.80
|
|
35
|
Role of gene-expression profiling in chronic myeloid leukemia.
|
Expert Rev Hematol
|
2009
|
0.79
|
|
36
|
The role of the e3 ligase cbl-B in murine dendritic cells.
|
PLoS One
|
2013
|
0.79
|
|
37
|
Re: Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
|
J Natl Cancer Inst
|
2005
|
0.78
|
|
38
|
Comment on "Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice".
|
J Immunol
|
2010
|
0.78
|
|
39
|
Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.
|
Cancer Immunol Immunother
|
2010
|
0.77
|
|
40
|
Medical decision analysis for first-line therapy of chronic myeloid leukemia.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
41
|
Complete or partial trisomy 3 in gastro-intestinal MALT lymphomas co-occurs with aberrations at 18q21 and correlates with advanced disease stage: a study on 25 cases.
|
World J Gastroenterol
|
2005
|
0.77
|
|
42
|
Myocardial ischaemia-reperfusion injury in haematopoietic cell-restricted beta1 integrin knockout mice.
|
Exp Physiol
|
2008
|
0.77
|
|
43
|
Non-Linear Association between Cerebral Amyloid Deposition and White Matter Microstructure in Cognitively Healthy Older Adults.
|
J Alzheimers Dis
|
2015
|
0.76
|
|
44
|
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.
|
BMJ Case Rep
|
2012
|
0.76
|
|
45
|
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
|
Am J Hematol
|
2015
|
0.76
|
|
46
|
CD4CD25 regulatory T cells: a new treatment option in glomerulonephritis.
|
Kidney Int
|
2005
|
0.76
|
|
47
|
Engineering effective T-cell based antitumor immunity.
|
Oncoimmunology
|
2013
|
0.76
|
|
48
|
Systematic assessment of decision-analytic models for chronic myeloid leukemia.
|
Appl Health Econ Health Policy
|
2014
|
0.76
|
|
49
|
Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.
|
Leuk Lymphoma
|
2005
|
0.76
|
|
50
|
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
|
Crit Rev Oncol Hematol
|
2011
|
0.76
|
|
51
|
Immune cells in colorectal cancer.
|
N Engl J Med
|
2006
|
0.75
|
|
52
|
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.
|
Haematologica
|
2012
|
0.75
|
|
53
|
Letters regarding article by Wojakowski et al, "mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction".
|
Circulation
|
2005
|
0.75
|
|
54
|
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.
|
Medicine (Baltimore)
|
2016
|
0.75
|
|
55
|
Increase of α-Secretase ADAM10 in Platelets Along Cognitively Healthy Aging.
|
J Alzheimers Dis
|
2016
|
0.75
|
|
56
|
More on remission of recalcitrant dermatomyositis treated with ruxolitinib.
|
N Engl J Med
|
2015
|
0.75
|
|
57
|
Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia.
|
Leuk Lymphoma
|
2008
|
0.75
|
|
58
|
Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report.
|
Urol Int
|
2016
|
0.75
|
|
59
|
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
|
Expert Rev Hematol
|
2011
|
0.75
|
|
60
|
Special edition myeloproliferative neoplasia - disease pathogenesis and treatment options.
|
Curr Cancer Drug Targets
|
2011
|
0.75
|
|
61
|
Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma.
|
Ann Hematol
|
2014
|
0.75
|
|
62
|
First annual report of the Austrian CML registry.
|
Wien Klin Wochenschr
|
2010
|
0.75
|